Table I.
Clinical and oral cGVHD characteristics of No oral cGVHD and Oral cGVHD study groups
| No oral cGVHD group | Oral cGVHD group | P value**** | |
|---|---|---|---|
| N = 5 | N = 5 | ||
| Age (years) | 51.4 ± 5.59, 45–59* | 52.2 ± 8.50, 42–64* | 1 |
| ORMS | 7.80 ± 4.82, 0–13 | 49.00 ± 17.06, 34–77 | 0.01 |
| Days from transplant | 592 ± 582, 132–1573 | 1396 ± 1345, 180–3667 | 0.3 |
| Disease** | 3 CML/Lymphoma | 3 CML/Lymphoma | - |
| 1 AML | 2 AML | ||
| 1 CLL | - | ||
| Cell source | 4 Peripheral Blood | 5 Peripheral Blood | - |
| 1 Bone Marrow | - | ||
| Donor relationship | Unrelated | 4 Unrelated | - |
| - | 1 Related | ||
| HLA match | 5 Matched | 3 Matched | - |
| - | 2 Mismatched | ||
| Oral histopathology | 4 of 4 biopsies taken showed no oral cGVHD | 2 of 2 oral biopsies taken showed oral cGVHD | - |
| Intensity of immunosuppression*** | 2.60 ± 1.52 | 3.20 ± 1.30 | 0.4 |
| Unstimulated salivary flow rate (ml/min) | 0.445 ± 0.126 | 0.394 ± 0.142 | 0.8 |
* Mean ± Standard Deviation, range
**Abbreviations: CML, chronic myeloid leukemia; AML, acute myelogenous leukemia; CLL, chronic lymphocytic leukemia
*** 1 = None, 2 = Mild (single agent prednisone < 0.5 mg/kg/day), 3 = Moderate (Prednisone ≥ 0.5 mg/kg/day and/or any single agent/modality), 4 = High (2 or more agents/modalities ± prednisone ≥ 0.5 mg/kg/day)
**** Mann–Whitney test